However, what works in a mouse will often not reflect the outcome in human patients with cancer. Therefore, comparative immunotherapy studies using veterinary patients may be better able to bridge murine and human studies. Many cancers in dogs and cats seem to be stronger models for their ...
dogsandcatsare more likely to predict treatment response and toxicity in people than are mouse models. Despite the hurdles that lie ahead, the reward will be worth the effort as the lives of people and animals with cancer are improved through a better understanding of the immune system and ...
Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the Western world [1]. For many years, the three major treatment modalities, surgery, radiotherapy and chemotherapy, have been the only standardized treatment options, with surgery being the only curative therapy. Al...
Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populations of patients who will respond and who will
The ideal cancer immunotherapy agent should discriminate between cancer and normal cells (specificity), be potent enough to kill small or large numbers of tumor cells (sensitivity), and prevent recurrence of a tumor (durability). 展开 关键词: Veterinary oncology Tumor immunotherapy Tumor immunology ...
The company plans to expand the indications of Vaxleukin to other types of cancer, including lymphoma, and is also developing an immunotherapy for cats.” With the approval of Vaxleukin-15 in Korea, VaxCell-Bio is set to pursue technology transfer, exports, and expansion into international ma...
BMC Cancer (2016) 16:940 Page 2 of 11 with simultaneous application of lipopolysaccharide (LPS) – the agonist of TLR4. The obtained synergy re- sulted in shrinkage and temporary or permanent dis- appearance of the tumors. LPS is well tolerated by rodents, dogs and cats [6], but causes...
But I thought that something like cancer would be more interesting as far as dealing with, kind of end-of-life issues. But also, just the idea of comparative medicine and the [idea that] things we learned in our dogs and cats can be applied to people. One of our kind of guiding ...
A xenogeneic melanoma-antigen-enhanced allogeneic tumor cell vaccine (ATCV) is an appealing strategy for anti-cancer immunotherapy due to its relative ease
As a known cell growth and activation factor for T cells and Natural Killer (NK) cells, IL-2 is one of the candidate cytokines used in cancer immunotherapy. It was the first cytokine licensed by FDA for the treatment of renal cell carcinoma and malignant melanoma. Efficacy of IL-2 is ...